BioSpace News Archive

Policy

AnGes Submits Application for Marketing Approval to PMDA for HGF Gene Therapy for Critical Limb Ischemia

The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan.

January 23, 2018
·
2 min read
BioMidwest

AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The net proceeds to AveXis from the offering, after deducting the underwriting discounts and commissions and other offering expenses payable by AveXis, are estimated to be approximately $431.9 million.

January 23, 2018
·
3 min read
Business

NeoChord Announces a Research Collaboration With the Skirball Center for Innovation at the Cardiovascular Research Foundation

The Cardiovascular Research Foundation is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education.

January 23, 2018
·
2 min read
Biotech Bay

Adamas Announces Proposed Public Offering of Common Stock

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

January 23, 2018
·
2 min read
Deals

Harvard Bioscience Pays $70M for Data Sciences International and Sells Denville Scientific

DSI is a life science research company focused on delivering preclinical products, systems, services and solutions to its customers.

January 23, 2018
·
13 min read
Pharm Country

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

In addition, Stemline intends to grant the underwriters a 30-day option to purchase up to an additional 555,000 shares of its common stock offered in the public offering.

January 23, 2018
·
4 min read
Drug Development

GENFIT: Official Launch of the NASH Pediatric Program, Following PIP and PSP Agreement by EMA and FDA

The PSP agreement by the FDA will lead to the launch of the first pediatric trial to evaluate the safety and efficacy of elafibranor in children with NASH.

January 23, 2018
·
7 min read
Pharm Country

Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 90% Mark for Reported Primary Events

Patients are being scheduled for final study visits commencing March 1, 2018. Amarin maintains its guidance to report top-line results from the study before the end of Q3 2018.

January 23, 2018
·
9 min read
Deals

Orion to Investigate Possible Sale of Orion Diagnostica

A possible result of the investigation may also be that Orion Diagnostica will continue as a part of the Orion Group.

January 23, 2018
·
1 min read
Domainex Wins Award to Develop GPCR Drug Discovery Technology

This investment represents a significant opportunity for the company to develop a technology to accelerate the discovery of new drugs.

January 23, 2018
·
1 min read